Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03738098 · ClinicalTrials.gov registry record · NA

NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children

A NA study of Genetic Predisposition to Disease and Genetic Diseases, Inborn, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
650
Enrollment target
2
Study locations

NCT03738098 is a NA study of Genetic Predisposition to Disease and Genetic Diseases, Inborn that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 650 participants, below the 182,465-participant average among 11 other Genetic Predisposition to Disease trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03738098, a NA study of Genetic Predisposition to Disease and Genetic Diseases, Inborn, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
650 participants
Enrollment target
2
Study locations

Study Summary

The NYCKidSeq program will significantly advance the implementation of genomic medicine, particularly for children, young adults and their families in Harlem and the Bronx. The study will assess the clinical utility of genomic medicine in three broad areas of pediatric disorders, while engaging a range of providers and community advisors to overcome the well-documented barriers to inclusion of underserved and underrepresented populations in genomic research. The study will also include testing, analyzing, and implementing a novel communication tool, Genomic Understanding, Information and Awareness (GUÍA), to facilitate the return of genomic test results. The use of GUÍA will enhance the understanding of these genomic testing results by families, patients, and care providers at all levels of expertise, in two health systems. Healthcare system leadership will be engaged to provide insights into their readiness for genomic implementation. Overall, the NYCKidSeq program will inform the genomics and clinical communities about how to implement genomic medicine in a diverse population in a clinically useful, technologically savvy, culturally sensitive, and ethically sound manner.

Interventions

  • BEHAVIORAL Standard of Care
  • BEHAVIORAL GUÍA

Study Locations (2)

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Albert Einstein College of Medicine/Montefiore - The Bronx

Trial Details

FieldValue
Enrollment Target 650 participants
Start Date 2019-01-30
Est. Completion 2022-04-28
Phase NA

What the Registry Record Tells You About NCT03738098

The ClinicalTrials.gov registry entry for NCT03738098 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182,465-participant average among 11 other Genetic Predisposition to Disease trials with a reported enrollment target (100% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Genetic Predisposition to Disease appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT03738098 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03738098 about?

NCT03738098 is a clinical study titled "NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children". The NYCKidSeq program will significantly advance the implementation of genomic medicine, particularly for children, young adults and their families in Harlem and the Bronx. The study will assess the clinical utility of genomic medicine in three broad areas of pediatric disorders, while engaging a ra...

What is the current status of trial NCT03738098?

This trial is currently completed. It is a NA study. The enrollment target is 650 participants. The study started on 2019-01-30. Estimated completion is 2022-04-28.

What conditions does trial NCT03738098 study?

This clinical trial studies the following conditions: Genetic Predisposition to Disease, Genetic Diseases, Inborn.

What interventions are being tested in trial NCT03738098?

The interventions under investigation include: Standard of Care (BEHAVIORAL), GUÍA (BEHAVIORAL).

Who is sponsoring clinical trial NCT03738098?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03738098 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Genetic Predisposition to Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.